BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Norak Biosciences, Inc. Issued Broader Rights To Transfluor Technology From New US Patent


10/19/2005 5:11:14 PM

RESEARCH TRIANGLE PARK, N.C., Aug. 5 /PRNewswire/ -- Norak Biosciences, Inc. announced today a newly issued U.S. patent covering compositions of matter that more broadly protect its Transfluor(R) technology. The newly issued patent 6,770,449 claims compositions (constructs) of any arrestin that is labeled by any method in a cell containing a GPCR capable of binding the arrestin. Labels specifically claimed include green fluorescent protein (GFP), beta-galactosidase, and luciferase.

By obtaining these new composition of matter claims, Norak will have both claims covering the compositions in its Transfluor(R) assay obtained in previously issued Norak patents and claims covering the making, using or selling of these compositions in the US regardless of the use contemplated for the compositions.

The U.S. patent follows on the heels of a broad European patent EP1015608 issued in March claiming compositions and cells including a conjugate of a beta-arrestin, including variants, and any detectable molecule, such as a fluorescent protein or enzyme moiety. Both patents are available for license.

"We now enjoy compositions of matter and methods claims covering Transfluor in the U.S., Europe and Australia," commented Dr. Roger. D. Blevins, Norak's president and CEO. "We are continuing to file and prosecute a range patents worldwide covering broader claims, modifications and improvements, as well as proprietary targets from our own research using Transfluor technology."

Norak's Transfluor(R) technology is a patented, universal GPCR drug discovery technology designed to be the most accurate method for discovering ligands for GPCR targets, whether known or orphan. Transfluor(R) was exclusively licensed in 1999 by Norak from technology developed at Duke University Medical Center and represents the combined research into GPCR signaling pathways over several decades by Norak's scientific founders, Drs. Marc Caron, Robert Lefkowitz, and Larry Barak.

About Norak:

Norak Biosciences, Inc., headquartered in Research Triangle Park, NC, is a private biotechnology company. Norak is utilizing its proprietary Transfluor(R) technology to become a worldwide leader in the discovery and development of drugs that regulate G protein-coupled receptors. For more information about Norak Biosciences, Inc., please visit the Company's website at http://www.norakbio.com/ .

Terry E. Willard Executive Vice President Norak Biosciences, Inc. 7030 Kit Creek Road Morrisville, NC 27560 Phone: 919 248 8000 x8804 Fax: 919 248 8033 twillard@norakbio.comhttp://www.norakbio.com/

Norak Biosciences, Inc.

CONTACT: Terry E. Willard, Executive Vice President of NorakBiosciences, Inc., +1-919-248-8000 x8804, or Fax, +1-919-248-8033, ortwillard@norakbio.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES